Cannabidiol Treatment for Refractory Seizures in Sturge-Weber syndrome

Publication date: Available online 22 February 2017
Source:Pediatric Neurology
Author(s): Emma H. Kaplan, Elizabeth A. Offermann, Jacqueline W. Sievers, Anne M. Comi
BackgroundSturge-Weber syndrome (SWS) results in leptomeningeal vascular malformations, medically-refractory epilepsy, stroke(s), and cognitive impairments. Cannabidiol (CBD), a cannabinoid without psychoactive properties, has been demonstrated in preclinical models to possibly have anticonvulsant, anti-oxidant, and neuroprotective actions.MethodsFive subjects with SWS brain involvement and treatment-resistant epilepsy were enrolled. Motor seizure frequency, quality of life (QoL), and adverse events were recorded from the 8 week pre-treatment period, 8 weeks after starting maintenance dose (Week 14), and most recent visit.ResultsFour subjects had data through Week 14; one of whom initially withdrew for lack of efficacy, but because of other benefits re-enrolled with a lower dose. Two subjects at Week 14 and three bilaterally brain involved subjects at last visit had greater than 50% seizure reduction, reported improved quality of life, and remain on CBD 63 to 80 weeks after starting drug. Three subjects reported mild side effects considered related to CBD.ConclusionThis study suggests that CBD may be well-tolerated as adjunctive medication for seizure management and provides initial data supporting further study of CBD in SWS patients.



http://ift.tt/2kOcDBx